|
Aug 7
|
Clinical trial supply chains in the US navigate pharma tariffs
|
|
Aug 5
|
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?
|
|
Jul 31
|
Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy
|
|
Jul 17
|
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors
|
|
Jul 16
|
BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target
|
|
May 8
|
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
|
|
May 6
|
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome
|
|
May 5
|
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
|
|
Jan 3
|
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
|
|
Oct 13
|
Denali Therapeutics Inc. (DNLI): Jeff Bezos Is Buying This Stock Now
|
|
Oct 7
|
Strength Seen in Voyager Therapeutics (VYGR): Can Its 17.5% Jump Turn into More Strength?
|
|
Sep 6
|
Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?
|
|
Sep 5
|
Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound?
|
|
Aug 26
|
Denali Therapeutics (NASDAQ:DNLI) shareholders are up 3.4% this past week, but still in the red over the last three years
|
|
Jul 23
|
Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?
|
|
Jun 24
|
Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?
|
|
May 11
|
The Consensus EPS Estimates For Denali Therapeutics Inc. (NASDAQ:DNLI) Just Fell Dramatically
|
|
May 9
|
Denali Therapeutics First Quarter 2024 Earnings: US$0.68 loss per share (vs US$0.80 loss in 1Q 2023)
|
|
May 8
|
Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus
|
|
May 7
|
Denali Therapeutics Q1 2024 Earnings: Misses Revenue Estimates Amid Strategic Shifts
|